AIM AIM ImmunoTech Inc

Price (delayed)

$0.403

Market cap

$20.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$20.72M

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease ...

Highlights
AIM ImmunoTech's gross profit has surged by 64% YoY but it has decreased by 11% QoQ
AIM ImmunoTech's gross margin has increased by 33% YoY but it has decreased by 6% from the previous quarter
AIM ImmunoTech's quick ratio has plunged by 93% YoY and by 26% from the previous quarter
AIM ImmunoTech's equity has shrunk by 86% YoY and by 53% QoQ

Key stats

What are the main financial stats of AIM
Market
Shares outstanding
51.28M
Market cap
$20.67M
Enterprise value
$20.72M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.08
Price to sales (P/S)
103.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
107.36
Earnings
Revenue
$193,000
EBIT
-$31.05M
EBITDA
-$30.58M
Free cash flow
-$22.43M
Per share
EPS
-$0.64
Free cash flow per share
-$0.45
Book value per share
$0.1
Revenue per share
$0
TBVPS
$0.28
Balance sheet
Total assets
$16.19M
Total liabilities
$11.36M
Debt
$3.35M
Equity
$4.83M
Working capital
$1.43M
Liquidity
Debt to equity
0.69
Current ratio
1.14
Quick ratio
1.11
Net debt/EBITDA
0
Margins
EBITDA margin
-15,843%
Gross margin
74.1%
Net margin
-16,123.3%
Operating margin
-17,261.7%
Efficiency
Return on assets
-128.3%
Return on equity
-183.6%
Return on invested capital
-547.4%
Return on capital employed
-491.8%
Return on sales
-16,086%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AIM stock price

How has the AIM ImmunoTech stock price performed over time
Intraday
3.33%
1 week
0.75%
1 month
-16.04%
1 year
-19.4%
YTD
-8.39%
QTD
-14.44%

Financial performance

How have AIM ImmunoTech's revenue and profit performed over time
Revenue
$193,000
Gross profit
$143,000
Operating income
-$33.32M
Net income
-$31.12M
Gross margin
74.1%
Net margin
-16,123.3%
AIM ImmunoTech's gross profit has surged by 64% YoY but it has decreased by 11% QoQ
The net income has plunged by 61% YoY and by 7% from the previous quarter
The operating income has plunged by 58% YoY and by 4.4% from the previous quarter
AIM ImmunoTech's gross margin has increased by 33% YoY but it has decreased by 6% from the previous quarter

Growth

What is AIM ImmunoTech's growth rate over time

Valuation

What is AIM ImmunoTech stock price valuation
P/E
N/A
P/B
4.08
P/S
103.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
107.36
The company's EPS has shrunk by 60% YoY and by 7% QoQ
AIM ImmunoTech's equity has shrunk by 86% YoY and by 53% QoQ
The P/B is 85% higher than the last 4 quarters average of 2.2
AIM's P/S is 64% below its 5-year quarterly average of 285.5 and 23% below its last 4 quarters average of 133.6
AIM ImmunoTech's revenue has increased by 24% YoY but it has decreased by 4.5% QoQ

Efficiency

How efficient is AIM ImmunoTech business performance
AIM's ROA has shrunk by 191% YoY and by 31% QoQ
The ROE has plunged by 55% from the previous quarter
The return on invested capital has declined by 41% since the previous quarter
The company's return on sales fell by 30% YoY and by 12% QoQ

Dividends

What is AIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AIM.

Financial health

How did AIM ImmunoTech financials performed over time
The total assets is 42% greater than the total liabilities
AIM's current ratio has dropped by 94% year-on-year and by 32% since the previous quarter
AIM ImmunoTech's quick ratio has plunged by 93% YoY and by 26% from the previous quarter
The debt is 31% smaller than the equity
AIM ImmunoTech's equity has shrunk by 86% YoY and by 53% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.